“Breakthrough Therapy Designation underscores the potential of SEP-363856 as a novel treatment for patients with schizophrenia, for whom few major advances in treatment have occurred since the ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced the initiation of its global Phase 2 program for SEP-363856, a novel, investigational psychotropic ...

The drug now known as SEP-363856 is being developed by Sunovion Pharmaceuticals Inc and PsychoGenics Inc. "Breakthrough Therapy Designation underscores the potential of SEP-363856 as a novel ...

An oral compound, SEP-363856, that does not act on dopamine D2 receptors but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT 1A ...

The novel antipsychotic agent SEP-363856 (Sunovion Pharmaceuticals) has a significant and ongoing effect on negative symptoms in patients with schizophrenia, new research shows. Results of a phase ...

Treatment with the investigational agent SEP-363856, a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, yielded far fewer adverse events compared with ...

While its exact mechanism of action is unknown, the two companies believe that SEP-363856 activates trace amine-associated receptor 1 (TAAR1) in addition to the serotonin receptor 5-HT1A without ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. The Food and Drug Administration (FDA ...

The pact sees Otsuka pay $270 million upfront with $620 million in biobucks for a development/sale deal for four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers ...